| Connect Hearing, Inc. | |
|
615 W Slaughter Ln Ste 116, Austin, TX 78748-2095 | |
| (512) 610-6156 | |
| (512) 610-6157 |
| Full Name | Connect Hearing, Inc. |
|---|---|
| Type | Facility |
| Speciality | Hearing Aid Equipment |
| Location | 615 W Slaughter Ln Ste 116, Austin, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992098149 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Connect Hearing, Inc. 750 N Commons Dr Ste 200, Aurora, IL 60504-7940 Ph: (630) 303-5380 | Connect Hearing, Inc. 615 W Slaughter Ln Ste 116, Austin, TX 78748-2095 Ph: (512) 610-6156 |
News Archive
Dr Stephen Martin and colleagues argue that this strategy is failing patients and wasting healthcare resources. They call for a re-examination of the threshold and urge clinicians to be cautious about treating low risk patients with blood pressure lowering drugs.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers using functional magnetic resonance imaging (fMRI) to study brain activation have found that men and women respond differently to positive and negative stimuli, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
› Verified 3 days ago